Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $283 |
| Triangulated Fair Value | $296 |
| 12-mo Scenario PWEV | $282 |
| Implied Return | +5% |
| Forward P/E | 14.0x |
| Market Cap | $55B |
| 52-Week Range | $244 – $376 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $441, +56% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($283) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Channel Disintermediation / Reimbursement' (20%) — targets $143, -49% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 84% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.48 vs analyst floor +0.00 → delta +0.48 (n=23 mgmt / 11 Q&A; 69th pctile across the S&P book, z +0.6).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.48 | +0.00 | +0.48 |
| 2026Q1 | +0.47 | +0.05 | +0.41 |
| 2025Q4 | +0.61 | +0.27 | +0.34 |
| 2025Q3 | +0.58 | +0.45 | +0.13 |
News (last 365d, 1000 articles): avg ticker sentiment +0.18 (bullish 23% / bearish 4%)
Scenario Analysis
The tree runs from a structural 'Structural — Channel Disintermediation / Reimbursement' downside ($143) to a 'Bull — Re-Rate' bull case ($441); the probability-weighted blend (PWEV $282) is -0% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Channel Disintermediation / Reimbursement | 20% | $143 | -49% |
| Volume / Generic-Deflation Pressure | 17% | $232 | -18% |
| Base — Drug-Volume + Specialty Growth | 35% | $297 | +5% |
| Growth — Specialty / Services Expansion | 20% | $375 | +32% |
| Bull — Re-Rate | 8% | $441 | +56% |
| Probability-Weighted (PWEV) | — | $282 | -0% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Channel Disintermediation / Reimbursement (20%, $143). Structural impairment — channel disintermediation / reimbursement: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 143.42; probability: 0.2.
- Volume / Generic-Deflation Pressure (17%, $232). Cyclical downturn — pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation weakens for 1–2 years before normalising. Drivers — implied_target: 231.98; probability: 0.17.
- Base — Drug-Volume + Specialty Growth (35%, $297). Mid-cycle — normalised pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation; disciplined capital allocation; steady returns. Drivers — implied_target: 296.65; probability: 0.35.
- Growth — Specialty / Services Expansion (20%, $375). Upside — specialty + services expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 374.55; probability: 0.2.
- Bull — Re-Rate (8%, $441). Upside tail — sustained tight conditions or a structural re-rate on specialty + services expansion. Drivers — implied_target: 440.52; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $248 | -12% |
| Peer P/E re-rate | multiple | $347 | +23% |
| Peer EV/Revenue re-rate | multiple | $354 | +25% |
| Scenario PWEV | multiple | $282 | -0% |
| DCF (5-year + terminal) | cash flow + terminal × | $312 | +10% |
| Triangulated (weighted) | — | $296 | +5% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $248 and 42% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (84% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.0%, 12x terminal FCF multiple → $312. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 17.24x) implies $347. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is tight (the methods corroborate one another).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Drug Distribution | $328.7B | 100% | 5% | 2% | 14x | 1% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation |
| net_debt_or_cash_b | -10.15 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.01 |
| div_yield | 0.0082 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | channel disintermediation / reimbursement |
| upside | specialty + services expansion |
Industry Context — Health Services
This name sits in the Health Services as a distributors. pharmaceutical distribution volumes + specialty/biosimilar mix + generic deflation Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: MCK (distributors) · COR (distributors) · CAH (distributors) · DGX (diagnostics) · LH (diagnostics) · HSIC (distributors)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Disintermediation Pressure | 37% | 37% | |
| Mid-Cycle — Volume + Specialty Growth | 35% | 35% | |
| Upside — Specialty / M&A Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Disintermediation Pressure () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $345B | $7B | $3B | $3B | $5B | $5B |
| FY+2 | $362B | $7B | $4B | $3B | $5B | $5B |
| FY+3 | $377B | $8B | $4B | $4B | $6B | $4B |
| FY+4 | $392B | $8B | $4B | $4B | $6B | $4B |
| FY+5 | $404B | $8B | $4B | $4B | $6B | $4B |
| Terminal | — | — | — | — | $6B × 12x | $48B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 1% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.0% · Σ PV(FCF) $22B + PV(terminal) $48B = EV $70B; + net cash → equity $60B ÷ diluted shares 0.19B = $312/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $450/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 5% vs WACC 8% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| MCK | 0.233x | 17.24x | 5% | 2% |
| CAH | 0.239x | 19.76x | 5% | 1% |
| HSIC | 0.982x | 15.65x | 5% | 6% |
| Median | 0.239x | 17.24x | — | — |
Peer-median fwd P/E → $347; EV/Rev → $354.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $312 | 41% | $128 |
| Scenario PWEV | $282 | 29% | $83 |
| Monte Carlo median | $248 | 18% | $44 |
| Peer P/E | $347 | 12% | $41 |
| Triangulated | — | 100% | $296 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 8.4x | 10.2x | 12.0x | 13.8x | 15.6x |
|---|---|---|---|---|---|
| 6% | $260 | $302 | $343 | $384 | $425 |
| 7% | $248 | $288 | $327 | $366 | $405 |
| 8% | $237 | $274 | $312 | $349 | $386 |
| 9% | $226 | $262 | $297 | $333 | $369 |
| 10% | $216 | $250 | $284 | $318 | $352 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $-225 | $28 | $280 | $533 | $786 |
| -1.5pp | $-243 | $27 | $296 | $565 | $834 |
| +0.0pp | $-262 | $25 | $312 | $598 | $885 |
| +1.5pp | $-282 | $23 | $328 | $633 | $938 |
| +3.0pp | $-303 | $21 | $346 | $670 | $995 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $-262 | $885 | $1,146 |
| Terminal × ±15% | $274 | $349 | $75 |
| Revenue CAGR ±3pp | $280 | $346 | $65 |
| WACC ±1pp | $297 | $327 | $29 |
| FCF conversion ±10% | $312 | $312 | $0 |
Company lever — SoP/share vs Drug Distribution multiple (AI re-rating) (base 14x)
| Multiple | 9.8x | 11.9x | 14.0x | 16.1x | 18.2x |
|---|---|---|---|---|---|
| SoP/share | $16,638 | $20,214 | $23,791 | $27,367 | $30,944 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 12×, FY+5 revenue $404B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $143.
Fact / Inference / Speculation
- FACT: Spot $283; 52-week range $244–$376; engine rating HOLD; base-case target $282 (-0%).
- INFERENCE: Triangulated FV $296 (+5%). Gross Margin explains 84% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 84% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $296 (+5% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (84% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).